Genotype-dependent disease progression in patients with B-CLL. Probability of disease progression as indicated by the time to first therapy (A) and overall survival (B) in 123 CLL patients displaying the BCL2−938CC or AC genotypes (n = 81) versus BCL2−938AA (n = 42) genotypes. Statistical analysis was performed using the log-rank test.